Biosimilars – Market Events And Forecast – Endocrinology

In 2019, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi will face increasing competition from insulin biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecasts for key reference brand insulins and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Endocrinology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Endocrinology Biologics (Insulin Analogues)
      • Terminology
      • Overarching Forecast Assumptions
        • Overview of Insulin Brands in Forecast
          • Overview of Approved Insulins
          • Biosimilar Entry Assumptions for Approved Insulins
        • Overview of Insulin Biosimilar Assumptions
        • Drug-Specific Forecast Assumptions
          • Lantus
            • Outlook for Lantus
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Lantus Sales Forecast in the United States: 2019-2029
            • Lantus Sales Forecast in the EU5: 2019-2029
            • Lantus Sales Forecast in Japan: 2019-2029
          • Levemir
            • Outlook for Levemir
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Levemir Sales Forecast in the United States: 2019-2029
            • Levemir Sales Forecast in the EU5: 2019-2029
            • Levemir Sales Forecast in Japan: 2019-2029
          • Humalog / Humalog Mix
            • Outlook for Humalog / Humalog Mix
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Humalog / Humalog Mix Sales Forecast in the United States: 2019-2029
            • Humalog / Humalog Mix Sales Forecast in the EU5: 2019-2029
            • Humalog / Humalog Mix Sales Forecast in Japan: 2019-2029
          • NovoLog / NovoRapid and NovoMix
            • Outlook for NovoLog / NovoRapid and NovoMix
            • First Major-Market Biosimilar Entrants (NovoLog and NovoRapid)
            • First Major-Market Biosimilar Entrants (NovoMix)
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • NovoLog / NovoRapid Sales Forecast in the United States: 2019-2029
            • NovoLog / NovoRapid Sales Forecast in the EU5: 2019-2029
            • NovoLog / NovoRapid Sales Forecast in Japan: 2019-2029
            • NovoMix Sales Forecast in the United States: 2019-2029
            • NovoMix Sales Forecast in the EU5: 2019-2029
            • NovoMix Sales Forecast in Japan: 2019-2029

      launch Related Market Assessment Reports